Sustained release preparation containing cilostazol and its preparation method

A sustained-release preparation, the technology of cilostazol, which is applied in the field of sustained-release preparations containing cilostazol and its preparation, can solve the problems of side effects of patients, easy oxidation of cilostazol and copolymers, etc.

Active Publication Date: 2007-08-15
SHENZHEN XINGYIN PHARML
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In order to overcome these defects, CN1168102A discloses a kind of resin particle that can continuously release the required amount of cilostazol in the body for a long time, and it realizes by incorporating cilostazol in ethylene vinyl alcohol copolymer. For the purpose of sustained release, it is mainly prepared by melting method, but organic solvents such as chloroform need to be used in the preparation of melting method, and the residue of these solvents will cause side effects to patients. Oxidation, these unfavorable factors have restricted its production and use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Cilostazol sustained-release tablets, calculated by 1000 tablets

[0016] Component Weight (g)

[0017] Cilostazol 200

[0018] Hydroxypropyl Methyl Cellulose K4M 70

[0019] Lactose 100

[0020] Magnesium stearate 3.5

[0021] Polyvinylpyrrolidone ethanol solution K-30 q.s

[0022] Preparation:

[0023] Raw and auxiliary materials are crushed and sieved, mixed with a lubricant, and compressed into tablets.

Embodiment 2

[0025] Cilostazol Sustained Release Tablets: Calculated by 1000 tablets

[0026] Component Weight (g)

[0027] Cilostazol 200

[0028] Hydroxypropyl Methyl Cellulose Methocl K4M 40

[0029] Hydroxypropyl Methyl Cellulose Methocl 100cp 40

[0030] Lactose 100

[0031] Magnesium stearate 3.5

[0032] Polyvinylpyrrolidone ethanol solution q.s

[0033] Preparation:

[0034] Raw and auxiliary materials are crushed and sieved, mixed according to the above prescription amount, made into granules, dried, sieved, and then mixed with a lubricant and pressed into tablets.

Embodiment 3

[0036] Cilostazol Sustained Release Tablets: Calculated by 1000 tablets

[0037] Component Weight (g)

[0038] Cilostazol 200

[0039] Hydroxypropyl Methyl Cellulose Methocl K4M 120

[0040] Microcrystalline Cellulose PH101 30

[0041] Lactose 50

[0042] Magnesium Stearate 4

[0043] Hypromellose ethanol solution (100cp) q.s

[0044] The preparation method is the same as in Example 2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of pharmaceutical preparation, and relates to a slow release preparation of Cilostazol, which comprises Cilostazol 35-60%, slow release material 10-60% and balancing medicinal adjuvant.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a slow-release preparation containing cilostazol and a preparation method thereof. Background technique [0002] The chemical name of cilostazol (cilostazol) is 6-[4-(1-cyclohexyl-1H-pentamethylene tetrazole (5')] butoxy-3,4-dihydro-1H quinolone (2'), and it is A new type of anti-platelet aggregation drug, by inhibiting the activity of phosphodiesterase in platelets and vascular smooth muscle, thereby increasing the concentration of cAMP in platelets and smooth muscle, exerting anti-platelet effect and vasodilator effect. This product inhibits ADP, epinephrine, collagen and peanut The platelet primary, secondary aggregation and release responses induced by tetraenoic acid are dose-related. The inhibition of platelet aggregation in vitro by oral administration of 100 mg cilostazol is 7-78 times stronger than that of the corresponding amount of aspirin (aspirin has no eff...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K9/48A61K31/4709A61P7/02
Inventor 高署
Owner SHENZHEN XINGYIN PHARML
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap